ERBB2 and breast cancer: The HR-positive/HER2-negative subtype accounts for 70% of breast cancer, while the HER2-positive and TNBC subtypes comprise 20%–25% and 15%–20% of breast cancer, respectively (Waks and Winer, 2019).